Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11131926 | 0.98 | SMN1; SMN2 (0.47) | SMN1; SMN2SCN1ASCN2ASCN3AGAA | |
| SCHEMBL11131918 | 0.98 | SMN1; SMN2 (0.47) | SMN1; SMN2SCN1ASCN2ASCN3AGAA | |
| SCHEMBL11131933 | 0.98 | SMN1; SMN2 (0.47) | SMN1; SMN2SCN1ASCN2ASCN3AGAA | |
| SCHEMBL18577147 | 0.84 | SLC18A3 (0.39) | SMN1; SMN2ALDH1A1SLC18A3NPSR1MEN1 | |
| SCHEMBL25971632 | 0.79 | SLC6A3 (0.37) | ALDH1A1SLC18A3NPSR1MEN1KMT2A | |
| SCHEMBL25971633 | 0.79 | SLC6A3 (0.37) | ALDH1A1SLC18A3NPSR1MEN1KMT2A | |
| SCHEMBL3073965 | 0.77 | DDB1 (0.36) | SMN1; SMN2GAAALDH1A1DDB1CRBN | |
| SCHEMBL3073967 | 0.77 | DDB1 (0.36) | SMN1; SMN2GAAALDH1A1DDB1CRBN | |
| SCHEMBL3073962 | 0.77 | DDB1 (0.36) | SMN1; SMN2GAAALDH1A1DDB1CRBN | |
| SCHEMBL25988650 | 0.76 | ALDH1A1 (0.44) | ALDH1A1HPGDHSD17B10NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700585-B2 | Derivatives of N-[phenyl(pyrrolidine-2-YL)methyl]benzamide and N-[(azepan-2-YL) phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-20 | — | — | US | disclosed |
| US-20070208006-A1 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-09-06 | — | — | US | disclosed |
| US-7226917-B2 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation, and use in treatment of schizophrenia | SANOFI-AVENTIS (FR) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208006-A1 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SNCA, CHRNA10, CHRNA5 | SMN1; SMN2 16/4885SCN1A 39/4885SCN2A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.